| Dr Thomas Weiner, MBBS | |
|
855 W Broad St Ste A, Athens, GA 30601-2511 | |
| (706) 850-6134 | |
| (706) 850-6318 |
| Full Name | Dr Thomas Weiner |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 18 Years |
| Location | 855 W Broad St Ste A, Athens, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1508187519 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MT198022 (Pennsylvania) | Secondary |
| 207Q00000X | Family Medicine | 072846 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospice Of Hilo | Hilo, HI | Hospice |
| Hilo Medical Center | Hilo, HI | Hospital |
| Kau Hospital | Pahala, HI | Hospital |
| Legacy Hilo Rehabilitation & Nursing Center | Hilo, HI | Nursing home |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Daiya Healthcare Pllc | 6002158615 | 108 |
| Ecare Hawaii Llc | 0648693051 | 6 |
News Archive
Sperm in the first fraction of ejaculate are more numerous, move more and present better quality DNA than those lagging behind. This is the conclusion of a study led by the Ginemed fertility clinic, which confirms that while the objective of the first fraction is to fertilise the egg, the second phase is so that no sperm from any other male has a chance to fertilise it.
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.
Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.
Researchers in the School of Medicine at the University of California, Riverside have identified an immune protein in mice that is quickly triggered in the body following infection and serves to protect the body's tissues. Called "RELMalpha," this protein, whose homologue in humans is called "resistin," is responsible more for protecting the body than attacking the parasite.
› Verified 6 days ago
| Entity Name | Bay Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689814022 PECOS PAC ID: 5890699037 Enrollment ID: O20031120000512 |
News Archive
Sperm in the first fraction of ejaculate are more numerous, move more and present better quality DNA than those lagging behind. This is the conclusion of a study led by the Ginemed fertility clinic, which confirms that while the objective of the first fraction is to fertilise the egg, the second phase is so that no sperm from any other male has a chance to fertilise it.
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.
Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.
Researchers in the School of Medicine at the University of California, Riverside have identified an immune protein in mice that is quickly triggered in the body following infection and serves to protect the body's tissues. Called "RELMalpha," this protein, whose homologue in humans is called "resistin," is responsible more for protecting the body than attacking the parasite.
› Verified 6 days ago
| Entity Name | Ecare Hawaii Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326660507 PECOS PAC ID: 0648693051 Enrollment ID: O20200701002707 |
News Archive
Sperm in the first fraction of ejaculate are more numerous, move more and present better quality DNA than those lagging behind. This is the conclusion of a study led by the Ginemed fertility clinic, which confirms that while the objective of the first fraction is to fertilise the egg, the second phase is so that no sperm from any other male has a chance to fertilise it.
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.
Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.
Researchers in the School of Medicine at the University of California, Riverside have identified an immune protein in mice that is quickly triggered in the body following infection and serves to protect the body's tissues. Called "RELMalpha," this protein, whose homologue in humans is called "resistin," is responsible more for protecting the body than attacking the parasite.
› Verified 6 days ago
| Entity Name | Daiya Healthcare Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477027381 PECOS PAC ID: 6002158615 Enrollment ID: O20200827001026 |
News Archive
Sperm in the first fraction of ejaculate are more numerous, move more and present better quality DNA than those lagging behind. This is the conclusion of a study led by the Ginemed fertility clinic, which confirms that while the objective of the first fraction is to fertilise the egg, the second phase is so that no sperm from any other male has a chance to fertilise it.
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.
Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.
Researchers in the School of Medicine at the University of California, Riverside have identified an immune protein in mice that is quickly triggered in the body following infection and serves to protect the body's tissues. Called "RELMalpha," this protein, whose homologue in humans is called "resistin," is responsible more for protecting the body than attacking the parasite.
› Verified 6 days ago
| Entity Name | Maika'i Health Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891301016 PECOS PAC ID: 5597153049 Enrollment ID: O20211102002544 |
News Archive
Sperm in the first fraction of ejaculate are more numerous, move more and present better quality DNA than those lagging behind. This is the conclusion of a study led by the Ginemed fertility clinic, which confirms that while the objective of the first fraction is to fertilise the egg, the second phase is so that no sperm from any other male has a chance to fertilise it.
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.
Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.
Researchers in the School of Medicine at the University of California, Riverside have identified an immune protein in mice that is quickly triggered in the body following infection and serves to protect the body's tissues. Called "RELMalpha," this protein, whose homologue in humans is called "resistin," is responsible more for protecting the body than attacking the parasite.
› Verified 6 days ago
| Entity Name | Mi-health Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154064855 PECOS PAC ID: 0143605030 Enrollment ID: O20220913002100 |
News Archive
Sperm in the first fraction of ejaculate are more numerous, move more and present better quality DNA than those lagging behind. This is the conclusion of a study led by the Ginemed fertility clinic, which confirms that while the objective of the first fraction is to fertilise the egg, the second phase is so that no sperm from any other male has a chance to fertilise it.
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.
Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.
Researchers in the School of Medicine at the University of California, Riverside have identified an immune protein in mice that is quickly triggered in the body following infection and serves to protect the body's tissues. Called "RELMalpha," this protein, whose homologue in humans is called "resistin," is responsible more for protecting the body than attacking the parasite.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Thomas Weiner, MBBS 855 W Broad St Ste A, Athens, GA 30601-2511 Ph: (706) 850-6134 | Dr Thomas Weiner, MBBS 855 W Broad St Ste A, Athens, GA 30601-2511 Ph: (706) 850-6134 |
News Archive
Sperm in the first fraction of ejaculate are more numerous, move more and present better quality DNA than those lagging behind. This is the conclusion of a study led by the Ginemed fertility clinic, which confirms that while the objective of the first fraction is to fertilise the egg, the second phase is so that no sperm from any other male has a chance to fertilise it.
BeiGene (Beijing), Co., Ltd., an innovative oncology company focused on developing targeted and immune-oncology therapeutics, today announced the achievement of a clinical milestone in the company's collaboration with Merck Serono, the biopharmaceutical division of Merck, Darmstadt, Germany, for BGB-283, a second-generation BRAF inhibitor candidate currently in Phase 1 development.
Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.
Researchers in the School of Medicine at the University of California, Riverside have identified an immune protein in mice that is quickly triggered in the body following infection and serves to protect the body's tissues. Called "RELMalpha," this protein, whose homologue in humans is called "resistin," is responsible more for protecting the body than attacking the parasite.
› Verified 6 days ago
Dr. Ron Elliott, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 55 Carlton St, Athens, GA 30602 Phone: 706-542-8621 Fax: 706-583-0217 | |
Dr. Garth Russo, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 55 Carlton St, Athens, GA 30602 Phone: 706-542-8621 Fax: 706-583-0217 | |
Mr. Errol Duncan, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 1061 Dowdy Rd, Suite 100, Athens, GA 30606 Phone: 706-621-7575 Fax: 706-621-7557 | |
Samuel C Griffin, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 700 Sunset Dr, Suite 101, Athens, GA 30606 Phone: 706-548-6068 Fax: 706-354-1218 | |
Ruth Adetoun Adene-peter, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 485 Highway 29 N, Athens, GA 30601 Phone: 706-438-4080 Fax: 706-438-4081 | |
Michael N Carter, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 892 Prince Ave, Athens, GA 30606 Phone: 706-227-2027 Fax: 706-227-2433 | |
Satya S Thippareddi, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 55 Carlton St, Athens, GA 30602 Phone: 706-542-8638 Fax: 706-542-8621 |